Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KAN-101

            Therapeutic Area: Immunology Product Name: KAN-101

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Bristol-Myers Squibb

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 22, 2020

            Details:

            The collaboration aims developing therapeutics for autoimmune diseases, to include Anokion’s lead antigen-specific drug candidate, KAN-101, for the treatment of celiac disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PHA121

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 09, 2020

            Details:

            The objective of the study was to investigate the ability of PHA121 to attenuate blood-pressure changes induced by bradykinin injection.